14 results about "Antituberculosis drug" patented technology

The invention belongs to the technical field of medical equipment, and particularly relates to a portable tuberculosis drug aerosol inhalation device. The device comprises a medicine storage chamber, an outflow channel and a controller, the top of the medicine storage chamber is provided with a medicine tank groove with a conical pricking pipe, and one-step medicine filling through placing and pressing can be achieved; the respiratory rhythm of a user is identified through lip contact and a respiratory airflow sensor, and the atomizer is synchronously controlled to start and stop; the system has the functions of liquid medicine identity recognition, heating temperature control and self-adaptive power adjustment based on liquid medicine storage, efficient, safe and comfortable tuberculosis medicine inhalation treatment is achieved, and the medication compliance and the treatment effect are remarkably improved.

The invention relates to a method for detecting six second-line antituberculous drugs by high performance liquid chromatography. The method comprises the following steps: providing an internal standard stock solution and a standard stock solution of six second-line antituberculosis drugs; preparing an internal standard working solution and a standard curve working solution by utilizing the diluent; preparing a solution of a product to be detected by using the Tianlongitudinal sample extraction liquid TZ-002; a liquid chromatograph is used for detection, and the conditions are as follows: a mobile phase A is a Tianlongitudinal sample releasing agent TZ-D004; a mobile phase B is acetonitrile; a mobile phase C is water; and gradient elution. According to the method, the plasma concentration of the second-line antituberculous drug taken by a tuberculosis patient is measured by applying the reversed-phase high-performance liquid chromatography, the cost is relatively low, the analysis time is short, the sensitivity is high, and the accuracy is high. The kit can be used for simultaneously detecting the blood concentration of six second-line antituberculosis drugs such as isopropylthioamide, levofloxacin, linezolid, moxifloxacin, deramanib and bedaquiline in human serum, and is expected to provide a more reliable basis for clinicians to adjust the dosage of the antituberculosis drugs.

FIELD: pharmacology.SUBSTANCE invention can be used to determine the concentration of an anti-tuberculosis drug in blood serum. The method for determining the concentration of bedaquiline in the blood serum in patients with tuberculosis or mycobacteriosis is that whole blood samples are centrifuged at 3000 rpm for 20 minutes, then the blood plasma is collected in sterile 1.5 mL Eppendorf tubes, then 900 mcL of acetonitrile are added to 300 mcL of plasma and centrifuged at 13500g for 15 minutes, then 1 mL of the supernatant is transferred to a chromatographic vial and make the assay by UHPLC MS / MS using an Athena UHPLC C18, 1.8 mcM, 120A, 2.1×100 mm chromatography column, when using an aqueous solution containing 5 g / L of ammonium acetate, 25 ml / L of concentrated acetic acid, 2 ml / L trifluoroacetic acid as mobile phase A and 100% acetonitrile as mobile phase B, the concentration of bedaquiline is determined using a pre-plotted calibration curve.EFFECT: determination of bedaquiline in human blood plasma in a time not exceeding 6 minutes.1 cl, 9 dwg, 6 tbl

The application provides a milk exosome coated PLGA nanometer anti-tuberculosis drug system and preparation and application. The system structure is: anti-tuberculosis drug-milk exosome@PLGA-anti-tuberculosis drug. The anti-tuberculosis drug is selected from a combination of one or more of aminoquinolones, benzothiazoles, arylquinolines, nitrobenzamide and benzothiazinone anti-tuberculosis drugs. The nanometer anti-tuberculosis drug system prolongs the circulation time of nanoparticles in blood, improves the bioavailability of the drug, enhances the cell uptake efficiency of nanoparticles, improves the drug delivery effect, reduces the immune rejection reaction and potential toxicity, and improves the safety of treatment.

The invention discloses a micromolecule polypeptide capable of inhibiting intracellular survival of mycobacterium tuberculosis and application of the micromolecule polypeptide, and belongs to the technical field of biology. The amino acid sequence of the micromolecule polypeptide is VLARYASICQ (SEQ ID NO.1), and the micromolecule polypeptide has cell penetrability, can promote glycolysis, and further inhibits the survival of mycobacterium tuberculosis in macrophages and mice. The micromolecule polypeptide can be used for preparing a medicine for resisting mycobacterium tuberculosis infection. The results of the invention can provide new tools and ideas for clinical prevention and treatment of tuberculosis, and especially have broad prospects in the aspects of development, clinical application and the like of anti-tuberculosis drugs. The invention has important application value for obtaining novel antituberculosis drugs.

The application discloses a glycosylation modified polyethylene imine and application thereof as an anti-tuberculosis drug. The glycosylation modified polyethylene imine provided by the application is obtained by reacting polyethylene imine with gluconolactone, and one or more amino groups on the polyethylene imine are modified with a gluconolactone group L (HOCH2(CHOH)4CO-). Further, the anti-tuberculosis activity, cytotoxicity and stability of the glycosylation modified polyethylene imine are verified through a series of experiments, and the experimental results show that the toxicity of the gluconolactone modified polyethylene imine to normal cells is obviously reduced, the polyethylene imine has high inhibitory activity to tubercle bacillus, and the polyethylene imine has good stability, so the polyethylene imine has great clinical application potential as a new anti-tuberculosis drug.

The invention belongs to the field of biological medicines, and particularly relates to application of dapinustat in preparation of a medicine for preventing and / or treating mycobacterium tuberculosis infection. In-vitro experiments prove that dapunostat has remarkable inhibitory activity on a mycobacterium tuberculosis standard strain, the minimum inhibitory concentration (MIC) is 1 mu g / mL, and the bactericidal effect of dapunostat under high bacterial load is superior to that of rifampicin. The dapinustat and the rifampicin have a synergistic effect. When dapunostat is combined with first-line antituberculosis drugs such as isoniazide, bedaquiline and ethambutol for use, drug effects are added. In addition, the dapunostat has no obvious toxicity to THP-1 human macrophages under an effective concentration. According to the invention, the new application of dapinustat in resisting mycobacterium tuberculosis is found for the first time, a brand new candidate drug and a drug combination scheme with known safety are provided for treatment of tuberculosis, especially drug-resistant tuberculosis, and the dapinustat has important clinical application value and development prospect.

The invention discloses application of phenothiazine compounds in preparation of antituberculosis drugs, and belongs to the technical field of biomedicine. The invention discloses application of phenothiazine compounds in preparation of antituberculous drugs, phenothiazine compounds X79 serve as a photosensitizer to mediate photodynamic therapy to generate active oxygen to achieve host-oriented treatment, a brand new treatment strategy is provided for infection of intracellular bacteria such as mycobacterium tuberculosis, biocompatibility is excellent, functional modification is easy to achieve, and the phenothiazine compounds X79 can be applied to preparation of antituberculous drugs. Good application prospects are realized in the field of tuberculosis treatment.

The invention provides a leucine dehydrogenase mutant and application thereof, and belongs to the technical field of bioengineering. The leucine dehydrogenase mutant provided by the invention can maintain higher catalytic stability in a wider pH value and temperature range, and the adaptability and durability of the leucine dehydrogenase mutant in an industrial reaction environment are remarkably improved. The improvement directly improves the efficiency and reliability of the process for catalytically synthesizing L-2-aminobutyric acid by using the enzyme, so that the reaction process is easier to control, and the cost loss caused by enzyme inactivation is potentially reduced. Finally, the mutant provides a catalyst with excellent performance for green, efficient and large-scale production of L-2-aminobutyric acid with high optical purity, so that a preparation process of chiral amino acid is simplified; and moreover, the method has important significance in reducing the production cost of key intermediates of downstream chiral drugs (such as certain antiepileptic drugs and antituberculosis drugs) and improving the product quality, and shows a good industrial application prospect.

The invention belongs to the technical field of medical equipment, and particularly relates to a portable tuberculosis drug aerosol inhalation device. The device comprises a medicine storage chamber, an outflow channel and a controller, the top of the medicine storage chamber is provided with a medicine tank groove with a conical pricking pipe, and one-step medicine filling through placing and pressing can be achieved; the respiratory rhythm of a user is identified through lip contact and a respiratory airflow sensor, and the atomizer is synchronously controlled to start and stop; the system has the functions of liquid medicine identity recognition, heating temperature control and self-adaptive power adjustment based on liquid medicine storage, efficient, safe and comfortable tuberculosis medicine inhalation treatment is achieved, and the medication compliance and the treatment effect are remarkably improved.

The invention discloses an application of a compound JQB-22 or a pharmaceutically acceptable salt thereof in preparation of antituberculosis drugs, and relates to the technical field of biological medicines. It is found that the compound JQB-22 has the effect of inhibiting intracellular survival of tubercle bacillus at the macrophage level, the anti-tuberculosis effect can be remarkably enhanced by regulating and controlling host immunity, and compared with a traditional first-line anti-tuberculosis drug ethambutol, the compound JQB-22 shows better control over the load of tubercle bacillus in lung tissue. The compound JQB-22 provided by the invention has the potential of being developed as an antituberculous drug. The invention provides an innovative research direction and a preclinical candidate drug for solving the treatment difficulty of the drug-resistant tuberculosis.

The invention belongs to the field of biological medicines, and provides an application of acetoacetic acid and derivatives thereof in preparation of medicines for treating or relieving hepatotoxicity caused by antituberculosis medicines. The hepatocytes formed by differentiation of human induced pluripotent stem cells are verified, and hydrazine is a metabolite with the strongest toxicity, so that the content of acetoacetic acid in the metabolite in the cells is reduced. Acetoacetic acid is one of main ketone metabolites in the ketone metabolism process, and cells can convert acetoacetic acid into acetoacetyl coenzyme A through succinyl coenzyme A: 3-oxo acid coenzyme A transferase. According to the invention, the OXCT1 gene in the human induced pluripotent stem cell is knocked out through CRISPR-cas9 and the human induced pluripotent stem cell is differentiated into the hepatocyte, so that the knockout of the OXCT1 gene increases the content of acetoacetic acid and reduces hepatic differentiation cell death caused by hydrazine.

A composition comprising a hypoxia-inducible factor prolyl hydroxylase inhibitor and an antituberculosis drug, and a use thereof in the preparation of medicines or health care products for preventing and treating chronic inflammatory anemia and infections. The obtained medicines or health care products can alleviate chronic inflammatory anemia caused by interference from mycobacterium tuberculosis, and can be used for treating tuberculosis.

The invention discloses a near-infrared hydrazine fluorescent probe and a preparation method and application thereof, according to the method, the near-infrared hydrazine fluorescent probe (CY-NH) for specific detection of N2H4 is synthesized, and the probe is constructed on the basis of hemicyanine derivatives and 2-thiophene carbonyl. When the N2H4 exists, the 2-thiophene carbonyl part of the probe CY-NH and the N2H4 are subjected to selective deprotection reaction, so that a fluorophore CY-OH is released, strong fluorescence emission is displayed in a near-infrared fluorescence region, and specific detection of the N2H4 is realized. The invention provides application of the hydrazine fluorescent probe in hydrazine visual detection. The hydrazine fluorescent probe can be used for visual detection of gaseous N2H4 and in-situ detection of N2H4 produced by metabolism of an antituberculosis drug isoniazide (INH) in living cells and zebra fish. Compared with the prior art, the method disclosed by the invention is simple to operate, good in biocompatibility and convenient in post-treatment, and has a great application prospect in the aspect of hydrazine detection.